Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…
List view / Grid view
High Throughput Screening (HTS)
11 April 2019 | By Pushpanathan Muthuirulan - Harvard University Cambridge
Automation offers a choice of powerful ways to design and execute high-quality laboratory research. The use of lab automation is now pervasive in biomedical labs, offering versatile platforms on which to perform an ever‑expanding array of tasks free of human errors, and a unique means to address the problems associated…
21 March 2019 | By NanoTemper Technologies
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
18 February 2019 | By Tecan and Ncardia
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development.
5 December 2018 | By BMG Labtech GmbH
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.
5 December 2018 | By Michael Kowalski (Global Project Manager at Beckman Coulter)
For drug discovery and biomarker research, screening campaigns are employed to identify potential new treatments for diseases and to answer questions that remain unknown in the scientific community.
1 December 2018 | By Dr David C. Murray (Hit Discovery - Discovery Sciences - IMED Biotech Unit - AstraZeneca), Dr Mark D. Wigglesworth (Hit Discovery - Discovery Sciences - IMED Biotech Unit - AstraZeneca)
Over the last five years drug discovery has undergone a rapid evolution from a closed and proprietary endeavour to an open and collaborative process. Large and small pharma now openly collaborate with each other and the wider academic world to leverage their collective depth of knowledge to increase the chances…
29 November 2018 | By Thermo Fisher Scientfic
This technical note demonstrates the feasibility of using the Thermo Scientific™Fluoroskan™ or Fluoroskan FL instruments with the Invitrogen™ Quant-iT™ dsDNAhigh-sensitivity assays. Sensitive and specific quantification of double-stranded DNA is carried out in microplate format. This is part of a series of technical notes aiming to help customers choose the best…
High throughput screening for deep mining of antibody repertoires, Dr. Stefan Moese, Novartis, Switzerland
9 November 2018 | By Beckman Coulter
In this webinar you learn about a high throughput screening approach for mining of antibody repertoires in the context of biologics drug discovery.
30 October 2018 | By BMG Labtech GmbH
In this webinar, we presented two examples of HTS in 1536-well plates, a screen for protein-protein interactions and a cell-based luciferase reporter assay.
3 October 2018 | By Drug Target Review
An international team of scientists has developed a candidate identification technique in the form of an algorithm that reduces the chances of rediscovering known compounds.
Application note: Miniaturisation of an HTRF methyltransferase assay that detects histone modifying activity
24 September 2018 | By BMG Labtech GmbH
High throughput screening is mostly done in pharmaceutical companies that test whole libraries of compounds. Reducing the assay volume will reduce operating costs. At the same time it is necessary to prove that the smaller volume will not have a negative impact on assay sensitivity and reliability.